You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
衞信康(603676.SH):多種維生素注射液(13)境內生產藥品註冊申請獲受理
格隆匯 12-28 15:42

格隆匯12月28日丨衞信康(603676.SH)公佈,近日,公司全資子公司內蒙古白醫製藥股份有限公司收到國家藥品監督管理局核准簽發的多種維生素注射液(13)境內生產藥品註冊受理通知書

多種維生素注射液(13)為多種維生素組成的複方製劑為靜脈用維生素補充劑適用於接受腸外營養的成人或11歲以上兒童的日常維生素補充

該品種的參比製劑SANDOZ. INFUVITE® ADULT2000年在美國上市以來一直在生產銷售並廣泛用於臨牀目前尚未進口中國。目前未見同名稱產品申報生產中。

該品種已上市的同類產品有注射用多種維生素(13)注射用多種維生素(12)注射用複方三維 B(II)注射用脂溶性維生素(II)注射用複方維生素(3)注射用脂溶性維生素(II)/注射用水溶性維生素組合包裝注射用水溶性維生素複方維生素注射液(3)脂溶性維生素注射液(II)複方維生素注射液(4)

根據米內網數據(注:全國放大版的中國城市及縣級公立醫院化學藥終端競爭格局)統計,2020多種維生素注射液(13)同類產品銷售額合計約34.44億元

截至20211130多種維生素注射液(13)累計投入研發費用約1478.66人民幣(未經審計)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account